

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Term	Documents
TNF.USPT.	4641
TNFS.USPT.	94
METHOTREXATE.USPT.	6124
METHOTREXATES.USPT.	16
(METHOTREXATE SAME TNF).USPT.	109

**Database:**

US Patents Full-Text Database

JPO Abstracts Database

EPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Refine Search:

('tnf') same methotrexate

[Clear](#)**Search History****Today's Date: 10/19/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT	('tnf') same methotrexate	109	<u>L2</u>
USPT	('tnf') and methotrexate	761	<u>L1</u>

REPORT SIMILAR ENTRIES  
FROM 10/16/00

**WEST**

Generate Collection

L3: Entry 97 of 357

File: USPT

Oct 27, 1998

US-PAT-NO: 5827742

DOCUMENT-IDENTIFIER: US 5827742 A

TITLE: Method of selecting pluripotent hematopoietic progenitor cells

DATE-ISSUED: October 27, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Scadden; David T.	Weston	MA	N/A	N/A

US-CL-CURRENT: 435/377; 435/2, 435/325, 435/366, 435/372, 435/375

## CLAIMS:

What is claimed is:

1. A method of selecting a population of mammalian cells containing quiescent pluripotent hematopoietic progenitor cells substantially free of mature, myeloid and lymphoid cells, comprising:
  - a) contacting a mammalian hematopoietic mononuclear cell suspension with an antibody specific for CD34 and maintaining said cell suspension with said antibody under conditions sufficient for the antibody to specifically bind to mononuclear cells expressing the cell surface antigen;
  - b) separating the antibody-bound cells from unbound cells and recovering the antibody bound cells thereby obtaining antibody positive mononuclear cells; and
  - c) culturing the antibody positive cells obtained in step b) in the combined presence of at least one anti-metabolite agent and at least one early-acting growth factor under conditions sufficient to eliminate dividing cells and cells responsive to early-acting growth factors, thereby selecting a population of cells containing quiescent pluripotent hematopoietic progenitor cells.
2. The method of claim 1 wherein the anti-metabolite agent is selected from the group consisting of 5-fluorouracil, bromodeoxy uridine, methotrexate, and .sup.3 H-thymidine.
3. The method of claim 1, wherein the mammalian hematopoietic mononuclear cell suspension is obtained from a human.
4. The method of claim 1 or 3, wherein the mammalian hematopoietic mononuclear cell suspension is obtained from a cell source selected from the group consisting of spleen, liver, thymus, bone marrow, umbilical cord blood, and peripheral blood.
5. The method of claim 1 or 2 wherein the early-acting growth factor is selected from the group consisting of kit ligand, stem cell factor, interleukin-3, interleukin-6, granulocyte-macrophage colony stimulating factor, interleukin-1, interleukin-11, flt-3 ligand and mpl ligand.